Ozempic’s Addiction Side Effect Stuns Researchers

A woman who worked in the wine industry started a weight-loss drug and suddenly couldn’t stand the taste of alcohol — and she isn’t alone.

Story Snapshot

People taking glucagon-like peptide-1 (GLP-1) drugs like Wegovy and Ozempic report losing cravings for alcohol, gambling, and other addictive behaviors as an unexpected side effect.
A large study of more than 600,000 U.S. veterans found that people on GLP-1 drugs were 14% less likely to develop a new substance use disorder than people on other diabetes drugs.
A small clinical trial found that a GLP-1 drug cut opioid cravings by 40% over just three weeks.
Experts warn that GLP-1 drugs are not approved by the Food and Drug Administration to treat addiction, and the research is still in early stages.

Real People, Real Results — But the Science Is Still Catching Up

Sharon Rhodes worked in the wine industry. She started taking Wegovy to lose weight. Then something strange happened. Alcohol started tasting metallic to her. She poured it out and didn’t look back, losing 32 kilograms in the process. Another woman, Chantal Pedley, lost 18 kilograms on Wegovy and stopped gambling entirely — despite working near a casino. She hadn’t set foot inside since starting the drug.

These stories are striking. They are also exactly the kind of reports that have scientists both excited and cautious. Personal accounts like these lit the fuse on a wave of research into whether GLP-1 drugs — the same ones millions take to lose weight or manage type 2 diabetes — might quietly rewire the brain’s relationship with addiction.

What the Research Actually Shows So Far

The science is young but it keeps pointing in the same direction. A study published in JAMA Psychiatry found that low-dose semaglutide reduced alcohol cravings and drinking in adults with alcohol use disorder, with researchers calling the results strong enough to justify larger trials. A separate small study found that patients with opioid use disorder on a GLP-1 drug called liraglutide experienced a 40% drop in opioid cravings over just three weeks. Stanford researchers note that early studies suggest GLP-1 drugs may help treat opioid, alcohol, and nicotine addiction.

The biggest data point so far comes from Washington University’s analysis of more than 600,000 U.S. veterans with type 2 diabetes. Veterans on GLP-1 drugs were 14% less likely than those on other diabetes drugs to develop any new substance use disorder — covering cannabis, alcohol, cocaine, and opioids. People who already had a substance use disorder and took GLP-1 drugs also saw lower rates of overdose and serious harm. That is not a small sample. That is a massive, real-world signal that something meaningful is happening.

Why Would a Weight-Loss Drug Kill an Addiction?

GLP-1 drugs work by mimicking a hormone your gut releases after eating. They tell your brain you are full. But the brain’s reward system — the same system hijacked by alcohol, drugs, and gambling — runs on some of the same pathways. Researchers believe GLP-1 drugs dial down the dopamine spike that makes addictive substances feel rewarding. In plain terms: the thing that makes drinking feel good gets quieter. The craving loses its pull.

National Geographic reported that GLP-1 drugs may not just reduce existing cravings — they may actually stop new addictions from forming in the first place by blunting how the brain encodes reward. That is a remarkable claim, and it fits what the veterans study showed. Clinicians at Brown University have described semaglutide as having “obliterated” cravings in some patients. The word “obliterated” is not typical scientific language — which tells you how striking the effect has been in some cases.

The Honest Caveat You Need to Hear

Here is what the researchers themselves insist you understand: GLP-1 drugs are not approved by the Food and Drug Administration (FDA) to treat addiction. Not for alcohol. Not for opioids. Not for gambling. The evidence is promising but still preliminary, and findings have been inconsistent across studies due to differences in patients and study design. Experts say it is too early to make clinical recommendations. The story of bupropion — an antidepressant that later became a smoking cessation drug — shows this path can work. But it takes rigorous, large-scale trials to get there, and those trials are just getting started.

The excitement is warranted. So is the patience. If GLP-1 drugs hold up in large randomized trials, they could reshape how America treats addiction — a crisis that kills tens of thousands every year. That is worth watching closely. It is not worth betting everything on yet.